Normoftal vs Davunetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Eye Peptide Bioregulator, Retina Peptide
Normoftal is an obscure Russian eye supplement from the Khavinson 'peptide bioregulator' tradition, sold as short peptides meant to support the retina. Be clear-eyed about this one: it is marketed as a dietary supplement, not an approved drug, and the evidence behind it is thin and comes almost entirely from one research lineage. We keep the claims minimal on purpose.
Also: NAP, AL-108
Davunetide (NAP) is an eight-amino-acid fragment (NAPVSIPQ) of activity-dependent neuroprotective protein (ADNP), discovered at Tel Aviv University and given as a nasal spray. It was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. Its big test, a phase 2/3 trial in progressive supranuclear palsy (PSP), failed cleanly in 2012, and development stalled. It has since been revived by its inventors, who argue it works in women and are pursuing ADNP syndrome, but those claims rest on reanalyses of old data, not a new successful trial.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Normoftal | Davunetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Khavinson's bioregulator theory holds that very short peptides (two to four amino acids) extracted from or modeled on a specific tissue can act as tissue-specific signals, switching gene expression and protein synthesis back toward normal in that organ. Normoftal is the eye/retina version, described as containing a synthesized peptide (marketed as 'AKS-G,' reportedly lysine and glutamic acid) intended to support retinal cells. The proposed mechanism is that the peptide corrects an age- or disease-related 'peptide deficiency' and restores normal cellular function in the retina. This is a hypothesis from one school of research, not a mechanism confirmed by independent molecular studies, and the specific composition claims come from vendors rather than peer-reviewed identification. | NAP comes from ADNP, a protein essential for brain development. In cell and animal studies it interacts with microtubule end-binding proteins (EB1 and EB3), promoting microtubule stability and reducing tau phosphorylation, which is why it was aimed at tauopathies like PSP and Alzheimer's disease. Mutations in the ADNP gene itself cause ADNP syndrome (Helsmoortel-Van der Aa syndrome), and in ADNP-deficient mice NAP improved some behavioral and neural measures, the rationale for that newer program. The PSP trial did not include target-engagement measures, so it never showed the drug was actually doing this in human brains. |
| Common Dosing | 2 capsules 1-2x daily 1-2x daily, before meals | 30 mg intranasal twice daily (PSP trial dose) Once or twice daily |
| Administration | Oral capsules, before meals | Intranasal spray (an IV form, AL-208, was tested in cardiac surgery) |
| Typical Duration | 30-day courses, repeat after 2-6 months | 12 weeks to 52 weeks in trials |
| Best Time to Take | Morning and evening, before meals | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Normoftal is sold in Russia as a dietary supplement and is marketed for retinal degeneration, glaucoma, cataracts, diabetic retinopathy, and post-surgical recovery. Here is the part that matters most: it is not FDA-approved, and the evidence for Khavinson-style retinal bioregulators is heavily concentrated within Khavinson's own institute and clinical program, not replicated by independent international groups to modern standards. The related pharmaceutical Retinalamin is registered for clinical use in Russia, but that registration reflects the Russian system, not FDA or EMA review. There are essentially no rigorous, independent, placebo-controlled trials specific to Normoftal itself in mainstream literature. Treat the marketed eye-health benefits as unproven claims, and treat confidence in this compound as low. | The headline result is negative. In the phase 2/3 PSP trial (Boxer and colleagues, Lancet Neurology 2014), 313 patients got 30 mg intranasal davunetide twice daily or placebo for 52 weeks. Disease progression was identical in both groups on both primary measures (PSP Rating Scale and Schwab and England daily living scale), and the authors concluded davunetide is not an effective treatment for PSP. Earlier phase 2 work was mixed: a 12-week trial in 144 people with amnestic mild cognitive impairment hinted at working-memory benefits, and a schizophrenia trial missed one co-primary endpoint while hitting another. The original developer, Allon Therapeutics, stopped investing and was later absorbed by Paladin Labs. The revival comes from the inventor's group: post hoc reanalyses of the PSP data (Translational Psychiatry 2023, Molecular Psychiatry 2026) report that women declined faster than men and that davunetide slowed decline in women only. A similar sex-split reanalysis of the MCI trial was published in 2024. These findings are interesting but are subgroup analyses of trials that failed overall, done by researchers tied to the company now developing the drug (ExoNavis Therapeutics), so they need a new prospective trial to mean much. ExoNavis has said a phase 3 in children with ADNP syndrome began in 2024, but Alzforum could not find it in trial registries. Davunetide holds FDA orphan and rare pediatric disease designations and EMA orphan status for ADNP syndrome. |
Frequently Asked Questions: Normoftal vs Davunetide
What is the difference between Normoftal and Davunetide?
Normoftal is a cognitive peptide that normoftal is an obscure russian eye supplement from the khavinson 'peptide bioregulator' tradition, sold as short peptides meant to support the retina. be clear-eyed about this one: it is marketed as a dietary supplement, not an approved drug, and the evidence behind it is thin and comes almost entirely from one research lineage. we keep the claims minimal on purpose. Davunetide is a cognitive peptide that davunetide (nap) is an eight-amino-acid fragment (napvsipq) of activity-dependent neuroprotective protein (adnp), discovered at tel aviv university and given as a nasal spray. it was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. its big test, a phase 2/3 trial in progressive supranuclear palsy (psp), failed cleanly in 2012, and development stalled. it has since been revived by its inventors, who argue it works in women and are pursuing adnp syndrome, but those claims rest on reanalyses of old data, not a new successful trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Normoftal or Davunetide?
Neither is universally "better" - the choice depends on your specific goals. Normoftal is typically used for cognitive purposes, while Davunetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Normoftal and Davunetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Normoftal and Davunetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.